Peritoneal (Abdominal Mesothelioma)
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases
Frontiers in Oncology 2021 June 18 [Link] Louis Gros, Petr Szturz, Antonella Diciolla, Volker Kirchner, Solange Peters, Niklaus Schaefer, Martin Hubner, Antonia Digklia Abstract Mesothelioma is a malignancy of serosal membranes. Parietal pleura is the most common site, with peritoneum being the second most frequent location. Malignant peritoneal mesothelioma (MPM) is a rare and aggressive…
Read MoreMonocytic Ontogeny of Regenerated Macrophages Characterizes the Mesotheliomagenic Responses to Carbon Nanotubes
Frontiers in Immunology 2021 June 14 [Link] Micaela Orsi, Mihaly Palmai-Pallag, Yousof Yakoub, Saloua Ibouraadaten, Michèle De Beukelaer, Caroline Bouzin, Bertrand Bearzatto, Jérôme Ambroise, Jean-Luc Gala, Davide Brusa, Dominique Lison, François Huaux Abstract Macrophages are not only derived from circulating blood monocytes or embryonic precursors but also expand by proliferation. The origin determines macrophage fate…
Read MoreCombined grade and nuclear grade are prognosis predictors of epithelioid malignant peritoneal mesothelioma: a multi-institutional retrospective study
Virchows Archive 2021 June 24 [Link] Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Averous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Françoise Galateau Sallé, Laurent Villeneuve, Olivier Glehen, Sylvie Isaac, Juliette Hommell-Fontaine Abstract Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. A recently described nuclear-grading system predicted survival…
Read MoreCytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up
International Journal of Hyperthermia 2021 [Link] Parisa Malekzadeh, Meghan Good, Marybeth S Hughes Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a lethal cancer, with approximately 2% of diagnoses occurring in patients less than 40 years of age. The purpose of this study is to report the only long-term follow up and survival of pediatric patients…
Read MoreIdentification of prognostic and bone metastasis-related alternative splicing signatures in mesothelioma
Cancer Medicine 2021 May 26 [Link] Runzhi Huang, Zixuan Zheng, Sijia Liu, Penghui Yan, Dianwen Song, Huabin Yin, Peng Hu, Xiaolong Zhu, Zhengyan Chang, Yihan Liu, Juanwei Zhuang, Tong Meng, Zongqiang Huang, Jie Zhang Abstract Mesothelioma (MESO) is an infrequent tumor derived from mesothelial cells of pleura, peritoneum, pericardium, and tunica vaginalis testis. Despite advancement…
Read MoreCytoreductive Surgery Plus HIPEC With and Without NIPEC for Malignant Peritoneal Mesothelioma: A Propensity-Matched Analysis
Annals of Surgical Oncology 2021 May 3 [Link] Paul H Sugarbaker, David Chang Abstract Background: Malignant peritoneal mesothelioma is a rare and often fatal disease. Dissemination is confined to the abdominal and pelvic peritoneal spaces in a great majority of patients. Methods: Standardized cytoreductive surgery and perioperative chemotherapy was used in all patients. Long-term normothermic…
Read MoreUnusually favorable outcome of 6 consecutive patients with diffuse malignant peritoneal mesothelioma treated with repeated doses of intraperitoneal paclitaxel. A case series
Surgical Oncology 2020 June [Link] Paul H Sugarbaker, O Anthony Stuart Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a disease in transition. Two decades ago this cancer had a median survival of 1 year. Recent reports in selected patients show a 5-year survival of 70% and median survival not reached at 10 years. Methods:…
Read MoreTertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis
Virchows Archiv 2021 April 14 [Link] Nazim Benzerdjeb, Peggy Dartigues, Vahan Kepenekian, Séverine Valmary-Degano, Eliane Mery, Gerlinde Avérous, Anne Chevallier, Marie-Hélène Laverriere, Irène Villa, Olivier Harou, Françoise Galateau Sallé, Laurent Villeneuve, Olivier Glehen, Sylvie Isaac 8, Juliette Hommell-Fontaine, Frédéric Bibeau Abstract Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant peritoneal mesothelioma. The relationship…
Read MoreEfficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
BMC Cancer 2021 March 20 [Link] Rui Kitadai, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Yusuke Nagata, Ryoichi Sawada, Atsuo Takashima, Narikazu Boku, Kan Yonemori Abstract Background: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed…
Read MoreOutcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BJS Open 2021 March 5 [Link] A Zahid, L Clarke, N Carr, K Chandrakumaran, A Tzivanakis, S Dayal, F Mohamed, T Cecil, B J Moran Abstract Background: Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, generally considered a borderline malignancy, best treated by cytoreductive surgery (CRS) to remove macroscopic disease, combined with hyperthermic intraperitoneal chemotherapy…
Read More